Literature DB >> 11030150

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.

O López-Ocejo1, A Viloria-Petit, M Bequet-Romero, D Mukhopadhyay, J Rak, R S Kerbel.   

Abstract

Like other types of pre-malignant lesions and carcinoma, angiogenesis is associated with high-grade cervical dysplasia and with invasive squamous carcinoma of the cervix. Vascular endothelial cell growth factor (VEGF) is known to be one of the most important inducers of angiogenesis and is upregulated in carcinoma of the cervix. Human Papilloma Virus 16 (HPV-16) has been etiologically linked to human cervical cancer, and the major oncogenic proteins encoded by the viral genome, E6 and E7, are involved in the immortalization of target cells. Because several oncogenes including mutant ras, EGF receptor, ErbB2/Her2, c-myc and v-src upregulate VEGF expression, we asked whether HVP-16 E6 oncoprotein could act in a similar fashion. We found that HPV-16 E6-positive cells generally express high levels of VEGF message. Furthermore, co-expression of the VEGF promoter-Luc (luciferase) reporter gene with E6 in both human keratinocytes and mouse fibroblast showed that E6 oncoprotein upregulates VEGF promoter activity, and does so in a p53 independent manner. An E6 responsive region which comprises four Sp-1 sites, between -194 and -50 bp of the VEGF promoter, is also necessary for constitutive VEGF transcription. Taken together, our results suggest the possibility that the HPV oncoprotein E6 may contribute to tumor angiogenesis by direct stimulation of the VEGF gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030150     DOI: 10.1038/sj.onc.1203817

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 2.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 3.  Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.

Authors:  Milind Rao; Wenxuan Yang; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

4.  Visible light optical spectroscopy is sensitive to neovascularization in the dysplastic cervix.

Authors:  Vivide Tuan-Chyan Chang; Sarah M Bean; Peter S Cartwright; Nirmala Ramanujam
Journal:  J Biomed Opt       Date:  2010 Sep-Oct       Impact factor: 3.170

5.  Interaction of Bartonella henselae with endothelial cells promotes monocyte/macrophage chemoattractant protein 1 gene expression and protein production and triggers monocyte migration.

Authors:  Amy M McCord; Andrew W O Burgess; Melissa J Whaley; Burt E Anderson
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Authors:  M Branca; C Giorgi; D Santini; L Di Bonito; M Ciotti; A Benedetto; P Paba; S Costa; D Bonifacio; P Di Bonito; L Accardi; C Favalli; K Syrjänen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

7.  Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer.

Authors:  Mayumi Sawada; Tetsuro Oishi; Hiroaki Komatsu; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Daiken Osaku; Tasuku Harada
Journal:  Int J Clin Oncol       Date:  2019-06-24       Impact factor: 3.402

8.  The transcription factor Net regulates the angiogenic switch.

Authors:  Hong Zheng; Christine Wasylyk; Abdelkader Ayadi; Joseph Abecassis; Jack A Schalken; Hermann Rogatsch; Nicolas Wernert; Sauveur-Michel Maira; Marie-Christine Multon; Bohdan Wasylyk
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

Review 9.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

10.  Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.

Authors:  Solomon Jo; Agnes Juhasz; Keqiang Zhang; Christopher Ruel; Sofia Loera; Sharon P Wilczynski; Yun Yen; Xiyong Liu; Joshua Ellenhorn; Dean Lim; Benjamin Paz; George Somlo; Nayana Vora; Stephen Shibata
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.